Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression

Efficacy of a Web-Based Intervention With Mobile Phone Support in Treating Depressive Symptoms in Adults With Type 1 and Type 2 Diabetes: A Randomized Controlled Trial

“…However, future studies should evaluate the individual additional impact of mobile phone support in an RCT. Moreover, the short-term effect on diabetes-related distress is higher in comparison with the Cochrane review, where no significant effect on the PAID could be shown (4).…”

“…A recent Cochrane review on psychological and pharmacological treatments in randomized trials showed that such an intervention can be an effective approach in reducing depressive symptoms (4). Eight studies reported depression effects for psychological interventions (range of standardized mean differences = 1.47-0.14), although between-study heterogeneity was substantial and the results were not pooled across studies (3).…”

Relationship of depression screening in cardiometabolic disease with vascular events and mortality: findings from a large primary care cohort with 4 years follow-up

“…However, there is no evidence to date that psychosocial therapies in the treatment of depression in patients with cardiometabolic disease has any beneficial effect on cardiovascular disease related physical outcomes or mortality (24)(25)(26). The overall rate of antidepressant initiation was higher for the unscreened 6.3% (4989/78936) when compared to those who were screened for depression 3.6% (1268/35537).…”

“…The potential influence of antidepressant prescribing on the findings of our study remains unclear. The Cochrane reviews on patients with CHD (24) and diabetes (25) have found no benefits of treating depressive symptoms with antidepressants on reducing all-cause mortality and cardiovascular related complications. For stroke patients, the evidence is very little with only one trial in patients with post stroke depression finding improvement in all-cause mortality for up to 9 years of follow-up with 8 weeks of antidepressants treatment compared against placebo (34).…”

1. Strategies for Improving Care

“…The prevalence of type 2 diabetes is two-three times higher in people with schizophrenia, bipolar disorder, and schizoaffective disorder than in the general population (70 (72). If a second-generation antipsychotic medication is prescribed, changes in weight, glycemic control, and cholesterol levels should be carefully monitored and the treatment regimen should be reassessed if significant changes are noted (73).…”